Abbelight announced it has closed a Series B financing round led by AVANT BIO, as the Paris-based company looks to accelerate product innovation and broaden commercial adoption of its super-resolution microscopy solutions across a wider customer base.
Abbelight develops end-to-end super-resolution imaging systems and “sample-to-insight” workflows that combine chemistry, optics and data analysis to help researchers visualize and quantify biological processes at the nanoscale. The company said it plans to tailor its imaging toolbox for additional growth verticals, including single-cell phenotyping and mechanism-of-action validation in drug discovery.
The funding is expected to support commercial expansion and customer support as Abbelight scales beyond its existing installed base of more than 100 systems. Abbelight said it serves both public research institutes and biotech customers, and aims to increase adoption across the broader bioindustry, including biopharma, biotech and contract research organizations.
Founded in 2016, Abbelight said it employs about 60 people and focuses on single-molecule localization microscopy (SMLM) and related nanoscopy technologies.
KEY QUOTES:
“With a decade of experience in the Life Science Research market, Abbelight has been transforming the way scientists see, quantify, and interpret all kinds of complex intracellular mechanisms.” “It’s now time to tailor our cutting-edge imaging toolbox to also address new key verticals, such as single cell phenotyping and mechanisms of action validation for drug discovery.”
Nicolas Bourg, CTO and Co-Founder, Abbelight
“Big things happen at the nanoscale – and Abbelight enables researchers to visualize precise sub-cellular structures like never before.” “Their breakthroughs in super-resolution microscopy and sample-to-insight workflows embody the kind of enabling technologies that accelerate discovery and drive innovation across life sciences.”
Daniella Kranjac, Founding General Partner, AVANT BIO
“This is an exciting moment for Abbelight. The funding accelerates our commercial expansion and allows us to continue delivering best-in-class support to our 100+ installed base.” “AVANT BIO’s support will be key to driving innovation and adoption across the broader bioindustry, including biopharma, biotech, and CROs”.
Jean-Baptiste Marie, CEO and Co-Founder, Abbelight
